Clinical Trial: A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07359820) titled 'A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement' on Jan. 16.

Brief Summary: The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement.

Participants will:

* Take lirafugratinib regularly as instructed by their study doctor.

* Visit the clinic as instructed for checkups and tests.

* Keep a diary recording each time a dose of lirafugratinib is taken.

Study Start Date: Feb., 2026

Study Typ...